IP Library Granted Patent US 11,065,369
Granted Patent B2
US 11,065,369 · App. 16/534,014 · Granted Jul 20, 2021

Bioabsorbable polymeric composition for a medical device

Inventors: G. Lawrence Thatcher (Chelmsford, MA); Robert J. Cottone (Davie, FL)
Assignee: ORBUSNEICH MEDICAL PTE. LTD.
A61L31/148A61F2/82A61F2/915A61K9/10A61L27/18A61L27/26A61L27/58A61L31/06A61L31/14A61L31/16A61L31/18B29C45/0053B29C48/0022B29C71/0063C08G63/91C08L67/00A61F2210/0004A61L2300/412A61L2300/606B29C2793/009B29C2793/0018B29K2067/046B29K2105/0085B29K2995/006B29K2995/0041B29L2031/7534C08L2203/02C08L2205/02Y10T428/139Y10T428/1352
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,065,369
App. No.
16/534,014
Granted
Jul 20, 2021
Kind
B2
Abstract

A crystallized bioabsorbable polymer scaffold comprises a polymer composition of poly (L-lactide-co-tri-methylene-carbonate) or poly (D-lactide-co-tri-methylene-carbonate) or poly (L-lactide-co-ε-caprolactone) or poly (D-lactide-co-ε-caprolactone) in the form of block copolymers of blocky copolymers, wherein the scaffold is cold-bendable.

Claims (6)

1. A bioabsorbable composition comprising a crystalline polymer composition, the polymer composition comprising: a poly (L-lactide) moiety, and/or a poly (D-lactide) moiety, and/or poly L-lactide-co-PEG moiety, and/or poly D-lactide-co-PEG moiety, linked or admixed with poly (L-lactide-co-Tri-methylene-carbonate) or poly (D-lactide-co-tri-methylene-carbonate) or poly (L-lactide-co-ε-caprolactone) or poly (D-lactide-co-ε-caprolactone) in the form of block copolymers or blocky random copolymers.

2. The bioabsorbable composition of claim 1 , further comprising a pharmaceutical agent.

3. The bioabsorbable composition of claim 2 , wherein the pharmaceutical agent comprises tacrolimus, sirolimus, everolimus, rapamycin, or mixtures thereof.

4. The bioabsorbable composition of claim 2 , wherein the pharmaceutical agent comprises a drug which inhibits smooth muscle cell migration and/or proliferation.

5. The bioabsorbable composition of claim 1 , wherein the polymer composition comprises poly (L-lactide), linked or admixed with poly (L-lactide-co-ε-caprolactone) in the form of block copolymers or blocky random copolymers.

6. A crystalline polymer composition, comprising: a poly (L-lactide) moiety, and/or a poly (D-lactide) moiety, and/or poly L-lactide-co-PEG moiety, and/or poly D-lactide-co-PEG moiety, linked or admixed with poly (L-lactide-co-Tri-methylene-carbonate) or poly (D-lactide-co-tri-methylene-carbonate) or poly (L-lactide-co-ε-caprolactone) or poly (D-lactide-co-ε-caprolactone) in the form of block copolymers or blocky random copolymers.

Assignments (2)
CHANGE OF ADDRESS Recorded Jun 15, 2022
From: ORBUSNEICH MEDICAL PTE. LTD.
To: ORBUSNEICH MEDICAL PTE. LTD.
Reel/Frame 060386/0417 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2019
From: THATCHER, G. LAWRENCE; COTTONE, ROBERT J.
To: ORBUSNEICH MEDICAL PTE. LTD.
Reel/Frame 050089/0100 →
Continuity (10)
Continuation 15840461 · Dec 13, 2017
Continuation 15457641 · Mar 13, 2017
Continuation 15298493 · Oct 20, 2016
Continuation 14542729 · Nov 17, 2014
Continuation 13370394 · Feb 10, 2012
Continuation 12508442 · Jul 23, 2009
Division 11781230 · Jul 20, 2007
Provisional Application 60862433 · Oct 20, 2006
Provisional Application 60807932 · Jul 20, 2006
Related Publication 20200237972A1 · Jul 30, 2020